Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/222223
Title: Prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN study
Author: Varela Rodríguez, Mar
Teixidó, Cristina
Álvarez Fernández, Carlos
Arasanz, Hugo
Peralta Muñoz, Sergio
Lázaro Quintelas, Martín
Calvo, Virginia
Álvarez Álvarez, Rosa
Baena, Javier
Valdivia Bautista, Javier
Arriola Aperribay, Edurne
Bernabé, Reyes
Isla, Dolores
Camacho, María del Carmen
Massuti, Bartomeu
Blasco, Ana
García Manrique, Teresa
Cobo, Manuel
Campayo Guillaumes, Marc
Hijazo Pechero, Sara
Callejo, Ángel
Domínguez, Marta
Nadal, Ernest
Keywords: Càncer de pulmó
Mutació (Biologia)
Oncogens
Lung cancer
Mutation (Biology)
Oncogenes
Issue Date: 21-Apr-2025
Publisher: AME Publishing Company
Abstract: Background: Geographic variability in epidermal growth factor receptor (EGFR) mutation rates in early-stage non-small cell lung cancer (NSCLC) has been reported. However, the frequency of EGFR mutations in patients with early-stage resected NSCLC in Spain has not been previously investigated. We aimed to determine the prevalence of EGFR mutations in patients with early-stage resected NSCLC in Spain. Methods: This was an observational, multicenter, cross-sectional study. Sensitizing EGFR mutations were assessed via real-time polymerase chain reaction (PCR)-based molecular analysis with the IdyllaTM TM EGFR Mutation Test , next-generation sequencing (NGS) analysis with the OncomineTM TM Precision Assay. Results: A total of 172 patients with surgically resected non-squamous NSCLC were analysed. Median age was 67.5 years , 57.6% were male, 96.5% had adenocarcinoma histology and 65% had stage IA/IB. EGFR mutations were found using IdyllaTM TM EGFR Mutation Test in 25 patients out of 172 patients (14.5%), which consisted of exon 19 deletion in 13 patients (7.6%), exon 21 L858R point mutation in 11 (6.4%), and exon 20 mutation (T790M) in 1 (0.6%) patient. The OncomineTM TM test was conducted in 128 patients, which detected exon 19 deletions in 10 patients (7.8%), exon 21 mutations in 10 patients (7.8%), and exon 20 insertions in 5 (3.9%) patients. The OncomineTM TM test was able to detect concurrent mutations in tumor suppressor genes ( TP53, PI3KCA, CDKN2A, PTEN) ) and another actionable alteration beyond EGFR, , such as mutations in KRAS G12C (22%), ERBB2 (6%), METex14 (2%), BRAF V600E (2%) and ALK and ROS1 fusions (2%, each). Conclusions: The prevalence of EGFR mutations in early stage (IA-IIIB), resectable, non-squamous NSCLC observed in our study is consistent with that reported in advanced NSCLC in Spain. Molecular testing is crucial in early-stage NSCLC and can be performed either with single-gene testing or NGS.
Note: Reproducció del document publicat a: https://doi.org/10.21037/tlcr-2024-1146
It is part of: Translational Lung Cancer Research, 2025, vol. 14, num. 4, p. 1254-1265
URI: https://hdl.handle.net/2445/222223
Related resource: https://doi.org/10.21037/tlcr-2024-1146
ISSN: 2226-4477
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Ciències Clíniques)

Files in This Item:
File Description SizeFormat 
tlcr-14-04-1254.pdf621.86 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons